Our top pick for
REGENXBIO Inc is a biotechnology business based in the US. REGENXBIO shares (RGNX) are listed on the NASDAQ and all prices are listed in US Dollars. REGENXBIO employs 257 staff and has a trailing 12-month revenue of around USD$144.9 million.
|52-week range||USD$20.03 - USD$50.26|
|50-day moving average||USD$44.5159|
|200-day moving average||USD$36.4516|
|Wall St. target price||USD$63.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.359|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing REGENXBIO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of REGENXBIO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
REGENXBIO's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.26. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into REGENXBIO's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$144.9 million|
|Gross profit TTM||USD$-97,193,000|
|Return on assets TTM||-12.6%|
|Return on equity TTM||-20.69%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 2.7 million REGENXBIO shares held short by investors – that's known as REGENXBIO's "short interest". This figure is 9.2% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting REGENXBIO shares can be evaluated.
REGENXBIO's "short interest ratio" (SIR) is the quantity of REGENXBIO shares currently shorted divided by the average quantity of REGENXBIO shares traded daily (recently around 432314.14634146). REGENXBIO's SIR currently stands at 6.15. In other words for every 100,000 REGENXBIO shares traded daily on the market, roughly 6150 shares are currently held short.
However REGENXBIO's short interest can also be evaluated against the total number of REGENXBIO shares, or, against the total number of tradable REGENXBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case REGENXBIO's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 REGENXBIO shares in existence, roughly 60 shares are currently held short) or 0.0932% of the tradable shares (for every 100,000 tradable REGENXBIO shares, roughly 93 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against REGENXBIO.
Find out more about how you can short REGENXBIO stock.
We're not expecting REGENXBIO to pay a dividend over the next 12 months.
Over the last 12 months, REGENXBIO's shares have ranged in value from as little as $20.03 up to $50.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while REGENXBIO's is 1.2076. This would suggest that REGENXBIO's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.